These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36669790)
1. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome. Gozes I; Shazman S Eur J Neurosci; 2023 Jul; 58(2):2641-2652. PubMed ID: 36669790 [TBL] [Abstract][Full Text] [Related]
2. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. Ivashko-Pachima Y; Ganaiem M; Ben-Horin-Hazak I; Lobyntseva A; Bellaiche N; Fischer I; Levy G; Sragovich S; Karmon G; Giladi E; Shazman S; Barak B; Gozes I Mol Psychiatry; 2022 Aug; 27(8):3316-3327. PubMed ID: 35538192 [TBL] [Abstract][Full Text] [Related]
3. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Ivashko-Pachima Y; Gozes I Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943 [TBL] [Abstract][Full Text] [Related]
4. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Gozes I Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667 [TBL] [Abstract][Full Text] [Related]
5. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743 [TBL] [Abstract][Full Text] [Related]
6. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. Hacohen-Kleiman G; Sragovich S; Karmon G; Gao AYL; Grigg I; Pasmanik-Chor M; Le A; Korenková V; McKinney RA; Gozes I J Clin Invest; 2018 Nov; 128(11):4956-4969. PubMed ID: 30106381 [TBL] [Abstract][Full Text] [Related]
7. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Gozes I Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282 [TBL] [Abstract][Full Text] [Related]
8. The ADNP Syndrome and CP201 (NAP) Potential and Hope. Gozes I Front Neurol; 2020; 11():608444. PubMed ID: 33329371 [TBL] [Abstract][Full Text] [Related]
15. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Shiryaev N; Pikman R; Giladi E; Gozes I Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979 [TBL] [Abstract][Full Text] [Related]
16. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Grigg I; Ivashko-Pachima Y; Hait TA; Korenková V; Touloumi O; Lagoudaki R; Van Dijck A; Marusic Z; Anicic M; Vukovic J; Kooy RF; Grigoriadis N; Gozes I Transl Psychiatry; 2020 Jul; 10(1):228. PubMed ID: 32661233 [TBL] [Abstract][Full Text] [Related]
17. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Merenlender-Wagner A; Shemer Z; Touloumi O; Lagoudaki R; Giladi E; Andrieux A; Grigoriadis NC; Gozes I Autophagy; 2014; 10(12):2324-32. PubMed ID: 25484074 [TBL] [Abstract][Full Text] [Related]
18. ADNP dysregulates methylation and mitochondrial gene expression in the cerebellum of a Helsmoortel-Van der Aa syndrome autopsy case. D'Incal C; Van Dijck A; Ibrahim J; De Man K; Bastini L; Konings A; Elinck E; Theys C; Gozes I; Marusic Z; Anicic M; Vukovic J; Van der Aa N; Mateiu L; Vanden Berghe W; Kooy RF Acta Neuropathol Commun; 2024 Apr; 12(1):62. PubMed ID: 38637827 [TBL] [Abstract][Full Text] [Related]
19. Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond. Kapitansky O; Giladi E; Jaljuli I; Bereswill S; Heimesaat MM; Gozes I J Neural Transm (Vienna); 2020 Feb; 127(2):251-263. PubMed ID: 32072336 [TBL] [Abstract][Full Text] [Related]